In addition, cetuximab in combination with chemotherapy has demonstrated a modest survival gain compared with chemotherapy alone in a phase 3 trial for chemotherapy-naive patients with EGFR-expressing advanced stage NSCLC (median survival 11.3 vs. 10.1 months, p = 0.044) (12). Here, EGFR is linked to non-small cell lung carcinoma.